The addition of thiazolidinediones, DPP4 inhibitors, or GLP-1 mimetics suggested as drugs to prevent PD may achieve more effective glycemic control, thus limiting the damaging effects of excess glycation on overall brain function. The gene discussed is GLP1R; the disease is Parkinson disease.